STOCK TITAN
  1. Home
  2. Sec-filings
  3. NRXP
  4. [8-K] NRX Pharmaceuticals, Inc. Reports Material Event

DARPA trial gives NRx Pharmaceuticals (NRXP) a shot at 15M-patient market

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

NRx Pharmaceuticals, Inc. reported financial results for the quarter and six months ended June 30, 2026, alongside a significant corporate update. For the six-month period, the company reported a net loss of $18.0 million compared with $23.1 million in 2025, while net operating loss increased to $11.3 million from $7.6 million due to higher R&D and commercial readiness expenses. Cash and cash equivalents rose to $26.7 million as of June 30, 2026 from $7.8 million at December 31, 2025, primarily driven by a public equity offering with more than $22 million in gross proceeds, supporting at least one year of operations.

The company advanced its ANDA for preservative-free ketamine, with the FDA citing no major drug or manufacturing deficiencies and only one container-related issue, which has been addressed. NRx is manufacturing 5 million units of launch stock with plans for 1 million units per month post-launch, targeting 2026 approval and commercialization. The NDA for NRX-100 is being finalized following federal support for using Real World Evidence, including data from 65,000 patients, with an approval goal in 2027. NRx was also selected as Prime Contractor for the DARPA SPARC-TMS phase 3 trial of NRX-101, potentially expanding its addressable depression market to more than 15 million Americans, and invested in Geneuro, Inc., gaining two clinical-stage monoclonal antibodies for ALS and other neurodegenerative and autoimmune conditions.

Positive

  • Cash and cash equivalents increased to $26.7 million from $7.8 million, supported by a public equity raise with more than $22 million in gross proceeds, and management states this provides funding for at least one year of operations.
  • The ANDA for preservative-free ketamine advanced with the FDA identifying no major deficiencies in the drug or its manufacture; launch manufacturing of 5 million units and planned 1 million units per month post-launch positions the product for a 2026 commercialization target.
  • Net loss for the six months ended June 30, 2026 improved to $18.0 million from $23.1 million in the prior-year period, reflecting lower impact from fair value and non-recurring convertible note-related charges.
  • Selection as Prime Contractor by DARPA for the SPARC-TMS phase 3 trial could expand NRX-101’s potential market from suicidal bipolar depression to treatment-resistant depression, with an addressable market of more than 15 million Americans.
  • The investment in Geneuro, Inc. adds two clinical-stage monoclonal antibody programs, including GNK-301 for ALS with a first-in-human trial targeted for July 2027, and benefits from U.S. and European governmental and research partnerships.

Negative

  • Net operating loss for the six months ended June 30, 2026 increased to $11.3 million from $7.6 million in 2025, driven by higher research and development expenses and rising selling, general and administrative costs tied to asset acquisition and commercial launch preparation.

Filing Explained

Any ATM use would add shares and reduce existing holders’ ownership percentages, but this filing reports capacity—not a completed ATM sale.

The filing identifies an active at-the-market facility as a possible financing route, not a reported sale: under this arrangement, the company may sell new shares gradually at prevailing prices.

As of June 30, 2026, cash and equivalents were approximately $26.7 million, equaling 270.6 days of the latest quarter's operating cash use; management's at-least-one-year assessment also relies on anticipated clinic revenue and opportunistic ATM use.

Sources and calculations
  • Cash and equivalents vs quarterly operating cash outflow, in days of cash use $26,686,000 / ($8,875,000 / 90) = [object Object]
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Net loss $18.0 million Net loss for the six months ended June 30, 2026 versus $23.1 million in 2025
Net operating loss $11.3 million Net operating loss for the six months ended June 30, 2026 versus $7.6 million in 2025
Cash and cash equivalents $26.7 million Cash balance as of June 30, 2026 versus $7.8 million as of December 31, 2025
Equity offering gross proceeds more than $22 million Public offering of common stock completed before June 30, 2026
Launch stock units 5 million units Initial manufacturing quantity for preservative-free ketamine launch stock
Post-launch monthly units 1 million units per month Planned production rate of preservative-free ketamine after launch
Real World Evidence population 65,000 Americans Data set used to support ketamine efficacy in depression
Addressable market for NRX-101 more than 15 million Americans Potential treatment-resistant depression market if SPARC-TMS trial is successful
Abbreviated New Drug Application (ANDA) regulatory
"The quarter’s key development was advancement of the ANDA for preservative-free ketamine"
An Abbreviated New Drug Application (ANDA) is the regulatory request a company files to get approval to market a generic version of an existing prescription drug by showing it has the same active ingredient, strength, dosage form and works the same in the body without repeating full clinical trials. Think of it as proving your copy of a recipe tastes and performs the same as the original. For investors, ANDA approvals determine whether a lower‑cost competitor can enter a market, affecting sales, pricing, patent disputes and the value of both the original drug maker and the generic entrant.
Real World Evidence regulatory
"guiding the FDA to use Real World Evidence for approval of ketamine"
Data about how a medical product performs in everyday use outside tightly controlled clinical trials, gathered from sources like medical records, insurance claims, patient reports, and device trackers. Investors care because this evidence can change how regulators, doctors and insurers view a product’s safety, effectiveness and value — like seeing how a car holds up on real roads versus a test track, which affects sales, approvals and reimbursement.
at-the-market offering facility financial
"opportunistic utilization of the Company's active at-the-market offering facility"
A program that lets a company sell newly issued shares directly into the open market at prevailing prices over time through a broker, rather than all at once. Think of it as a faucet that lets the company draw small, on-demand amounts of cash when needed. Investors care because it provides flexible, lower-cost fundraising but increases the total shares outstanding — which can reduce existing holders’ ownership and may influence the stock price.
Breakthrough Therapy Designation regulatory
"NRX-101 has been awarded Breakthrough Therapy Designation for the treatment"
A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.
Fast Track Designation regulatory
"NRX-100 has been awarded Fast Track Designation for the treatment"
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.
Congressionally-Directed Medical Research Program medical
"selected in the first round of the Congressionally-Directed Medical Research Program"
Offering Type other

FAQ

What were NRx Pharmaceuticals (NRXP)'s net loss figures for the six months ended June 30, 2026?
NRx Pharmaceuticals reported a net loss of $18.0 million for the six months ended June 30, 2026, compared with $23.1 million in the same period of 2025. The improvement mainly reflects reduced impacts from fair value measurements and non-recurring convertible note restructuring charges present in 2025.

How did NRx Pharmaceuticals (NRXP)'s operating performance change in the first half of 2026?
NRx Pharmaceuticals recorded a net operating loss of $11.3 million for the six months ended June 30, 2026, versus $7.6 million a year earlier. The higher loss was driven by increased R&D linked to acquired assets and higher SG&A spending for anticipated ketamine commercialization.

What is NRx Pharmaceuticals (NRXP)'s cash position and liquidity outlook as of June 30, 2026?
As of June 30, 2026, NRx Pharmaceuticals held $26.7 million in cash and cash equivalents, up from $7.8 million at December 31, 2025. This increase was largely due to a public stock offering exceeding $22 million, and management believes current resources support at least one year of operations.

What progress has NRx Pharmaceuticals (NRXP) made on its preservative-free ketamine ANDA and NDA?
The FDA reported no major deficiencies in the preservative-free ketamine drug or manufacturing, requesting only a vial component attestation, which NRx has provided. The company targets 2026 ANDA approval and is finalizing an NDA for NRX-100 with a 2027 approval goal using Real World Evidence.

How could the DARPA SPARC-TMS trial impact NRx Pharmaceuticals (NRXP)'s NRX-101 opportunity?
NRx was selected as Prime Contractor for DARPA’s SPARC-TMS phase 3 trial evaluating NRX-101 with robotic TMS. Positive results could expand NRX-101’s use from suicidal bipolar depression to treatment-resistant depression, potentially addressing a market of more than 15 million U.S. patients.

What new pipeline assets did NRx Pharmaceuticals (NRXP) gain through its Geneuro investment?
NRx invested in Geneuro, Inc., obtaining access to two clinical-stage monoclonal antibodies, including GNK-301 for ALS and Temelimab for multiple sclerosis, Type 1 diabetes, and schizophrenia. GNK-301’s first-in-human trial is targeted for July 2027, with additional support from U.S. NIH and European partners.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
false 0001719406 0001719406 2026-08-17 2026-08-17
 
 
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): August 17, 2026
 
 
NRX PHARMACEUTICALS, INC.
 
 
(Exact name of registrant as specified in its charter)
 
 
 
Delaware
 
001-38302
 
82-2844431
 
 
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(I.R.S. Employer
Identification Number)
 
 
 
1201 Orange Street, Suite 600
Wilmington, Delaware
 
19801
 
 
(Address of principal executive offices)
 
(Zip Code) 
 
 
(484)254-6134
(Registrant’s telephone number, including area code) 
 
Not applicable
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.424)
 
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act: 
 
Title of each class
 
Trading Symbol
 
Name of exchange on which registered
 
 
 
 
 
Common Stock, par value $0.001 per share
 
NRXP
 
The Nasdaq Stock Market LLC
 
 
 
 
 
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
Item 2.02 Results of Operations and Financial Condition.
 
On August 17, 2026, NRx Pharmaceuticals, Inc. (the “Company”) announced via press release its results for the second quarter ended June 30, 2026. A copy of the Company’s press release is hereby furnished and incorporated herein by reference as Exhibit 99.1.
 
Item 9.01. Financial Statements and Exhibits.
 
Exhibit 
No.
 
Description
 
 
 
99.1
 
Press Release dated August 17, 2026.
104
 
Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
NRx Pharmaceuticals, Inc.
 
 
 
 
 
Date: August 17, 2026
By:
/s/ Jonathan Javitt
 
 
Name:
Jonathan Javitt
 
 
Its:
Chief Executive Officer
 
 

Exhibit 99.1

 

logo.jpg

 

NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET

 

Key recent and second quarter highlights include:

 

●

Completed first-cycle FDA review of the Company’s ANDA for preservative-free ketamine with no drug-related major deficiencies. The sole remaining item, a manufacturer's attestation on the vial, has been submitted to FDA.

 

●

Initiation of commercial scale manufacturing of preservative-free ketamine building to launch stock of 5 million doses to be ready for commercialization in 2026.

 

●

Selected by the Defense Advanced Research Projects Agency (DARPA) as prime contractor for SPARC-TMS, an FDA-approved Phase 2/3 trial of NRX-101 with robotic TMS. Anticipated non-dilutive funding exceeds $11.5 million, subject to completion of contracting

 

●

The Company is advancing its NRX-100 NDA on Real World Evidence from more than 65,000 patients, leveraging a Presidential Executive Order and Congressional budget language that encourage FDA use of such evidence in approving treatments for depression.

 

●

Closed an institutionally-supported, underwritten public offering of common stock for gross proceeds of $22.3 million, including full exercise of the underwriters’ option. The Company expects existing cash to fund operations for at least one year.

 

●

HOPE Therapeutics expanded its clinical footprint with new sites in Sarasota and Boca Raton, Florida, and became the first commercial site in the US to treat patients using Zeta Surgical’s FDA-cleared TMS navigation system.

 

●

Appointed Glenn Tyson as the Company’s first Chief Commercial Officer and retained a commercial launch team for preservative-free ketamine.

 

 

WILMINGTON, DE August 17, 2026 – NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx”, the “Company”, “we”, “us” or “our”) a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended June 30, 2026, and provided a corporate update. The quarter was marked by significant progress on multiple fronts and strengthening of the Company’s balance sheet to provide adequate funds for at least one year of operations and commercial launch.

 

 

logo.jpg

 

The quarter’s key development was advancement of the ANDA for preservative-free ketamine toward FDA approval and commercialization, which would represent a transformational milestone . The FDA identified no major deficiencies related to the drug or its manufacture. A single major deficiency was identified related to the luer lock component of the vial (i.e. the element of the drug container that connects to a syringe) wherein FDA requested that the Company provide a manufacturer’s attestation that the vial is manufactured in the same manner as it is for 3 other currently approved drugs that ship more than 11.9 million units per year. This attestation has been provided to the FDA and the Company aims for 2026 approval and commercialization. Accordingly, five million units of launch stock is currently in the manufacturing process with anticipated post launch manufacture of 1 million units per month.

 

NRx has continued to advance its New Drug Application for NRX-100 (Preservative-free ketamine) to treat depression. During Q2, a Presidential Executive Order was signed and Congressional Budget Language was approved guiding the FDA to use Real World Evidence for approval of ketamine to treat depression. Evidence gathered from 65,000 Americans was presented at the American Society of Clinical Psychopharmacology meeting in Miami demonstrating that intravenous ketamine has greater or comparable efficacy to intranasal S-ketamine with more rapid onset in treating depression. With alignment on the drug packaging matter, the Company is now poised to finalize its NDA, aiming for 2027 approval.

 

In a potentially federally-funded expansion of the Company’s business plan for NRX-101, (D-cycloserine/lurasidone) NRx was selected as Prime Contractor by the Defense Advanced Research Projects Agency for the SPARC-TMS trial led by Prof. Josh Brown, the Company’s Chief Medical Innovation Officer in partnership with Harvard McClean Hospital and multiple US Military Treatment Facilities. SPARC-TMS measures the efficacy of the Company’s neuroplastic drug (NRX-101) in combination with robotic assisted TMS (www.clinicaltrials.gov NCT 07227103). Successful clinical results could lead to widespread adoption of NRX-101+Robotic TMS for treatment of depression in the military, first responder organizations, and the general population, with initial published results rivaling or exceeding psychedelic drugs. Until now, NRX-101 was positioned only for the treatment of suicidal bipolar depression, a sub million patient market. This military partnered and FDA-approved phase 3 trial potentially expands the market for NRX-101 to all patients with treatment-resistant depression, with an addressable market of more than 15 million Americans (see www.nrxdefense.com).

 

NRx invested in the formation of Geneuro, Inc., with two clinical-stage monoclonal antibody drugs to treat ALS (GNK-301), Schizophrenia (Temelimab®), Multiple Sclerosis, and Type 1 Diabetes (see www.geneuro.us). These patented biologics target Human Endogenous RetroVirus (HERV) envelope proteins that are shown to be neurotoxic and etiologic in neurodegenerative disorders. Temelimab has shown promising, validating clinical results in now-completed European trials for treatment of multiple sclerosis and Type-1 Diabetes. In partnership with the Fondation FondaMental (Paris, FR) and French government funding, GeNeuro aims to launch a clinical trial of Temelimab to treat Schizophrenia. GNK-301 was co-invented at the US National Institute for Neurologic Diseases and Stroke and GeNeuro is partnered with the US National Institutes of Health. GeNeuro, Inc. has already been selected in the first round of the Congressionally-Directed Medical Research Program for drug development and biomarker funding. GNK-301’s first-in-human trial is targeted for July 2027. Should initial clinical activities succeed, substantial funds have been added to the 2027 Defense appropriation to support ongoing activities.

 

 

logo.jpg

 

“The second quarter of 2026 was a major inflection point for NRx as we advance our mission to bring hope to the most vulnerable patients battling depression and suicidal ideation,” said Dr. Jonathan Javitt, the Company’s CEO and Chairman. “We have continued to drive towards our key objective of first commercial ketamine sales in 2026 with corresponding manufacturing operations and build-out of our first commercial team. Our path to approval of NRX-100 has been advanced by support from the White House and Congress for the use of Real World Evidence that our drug has comparable or superior efficacy to that of current market leaders. Our partnership with the Department of War and its Defense Advanced Research Projects Agency led by Prof. Brown and Dr. Dennis McBride is the culmination of a multi-year endeavor. Similarly, our acquisition of the GeNeuro assets and the resulting partnership with NIH offers a clinical stage and potentially humanity-changing opportunity for the Company – including potentially the first disease-modifying drug to treat ALS – in ALS and other serious disorders, with strong governmental partnership and support from non-dilutive sources of capital. Combat veterans face a two-fold increased risk of ALS, and advancing a cure remains a high priority with strong Congressional support.”

 

Financial Results for the Quarter Ended June 30, 2026

 

For the six months ended June 30, 2026, NRx reported a net loss of $18.0 million, versus a net loss of $23.1 million during the comparable period in 2025. The change was primarily related to the impact of certain fair value accounting measurements and other non-recurring charges related to the conversion and restructuring of previously issued convertible notes incurred during the six months ended June 30, 2025. For the six months ended June 30, 2026, NRx reported a net operating loss of $11.3 million versus a net operating loss of $7.6 million for the comparable period in 2025. The change was primarily driven by certain research and development costs related to the acquisition of certain assets which management believes will drive significant long-term value for shareholders, as well as increased selling, general and administrative costs including, but not limited to, the addition of key personnel and other expenses related to the Company’s anticipated commercial launch of its ANDA for preservative-free ketamine. As of June 30, 2026, the Company had approximately $26.7 million in cash and cash equivalents versus $7.8 million as of December 31, 2025. The increase was primarily related to the Company’s completion of a public offering of common stock with gross proceeds of more than $22 million. Management believes current cash resources, anticipated growth in clinic revenue, and opportunistic utilization of the Company's active at-the-market offering facility will be sufficient to support operations for at least one year.

 

 

logo.jpg

 

Conference Call Details

 

The Company will host a conference call at 4:30pm ET on Monday, August 17, 2026.

 

In addition to reviewing the Company's financial results for the fiscal year ended December 31, 2025, the Company will provide an update on the significant progress achieved across its drug development programs and the HOPE Therapeutics clinical network, milestones that bring the Company closer to its founding mission of preventing suicide and transforming the treatment of depression and PTSD to improve the lives of patients and bring hope to life.

 

A live webcast of the conference call will be available on the Company’s website at https://ir.nrxpharma.com/events. Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically 1-800-717-1738 or internationally +1-646-307-1865.

 

About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA), and initiated a New Drug Application filing for NRX-100 with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal ideation in patients with depression, including bipolar depression.

 

Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

 

For further information:

Brian Korb

Managing Partner, astr partners
(917) 653-5122

brian.korb@astrpartners.com

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

5 documents

Press Releases

Other Documents